Cajie Powder veterinary-grade API is first assessed for particle size distribution by laser diffraction in accordance with ISO 13320:2020, bulk density and tapped density by USP <616> or Ph. Eur. 2.9.34, and compressibility index by Ph. Eur. 2.9.36. The formulation addition ratio is not a fixed parameter; it is calculated as % w/w = (target unit dose (mg) / total tablet core weight (mg)) × 100. For a high-loading veterinary tablet, development batches commonly evaluate 10–45% w/w of Cajie Powder, but the final ratio is locked only after dose-confirmation batches and in-process uniformity data. If direct compression flow is inadequate, wet granulation is selected: the mixed internal phase is granulated in a high-shear mixer with impeller tip speed of 3–6 m/s, chopper at 800–1,200 rpm, and binder solution at 2–5% w/v until an endpoint torque rise of 0.5–1.5 kW on a 600 L mixer. The wet mass is dried in a fluidized-bed dryer to a product temperature of 30–35°C and loss on drying of 1.5–2.5%, then milled through a 0.8–1.2 mm screen. Compression is performed on a rotary tablet press with main compression force of 8–14 kN, precompression at 2–3 kN, and turret speed of 30–50 rpm. Tablet cores must meet USP <905> uniformity of dosage units, Ph. Eur. 2.9.40 content uniformity, and dissolution release limits per USP <711> or Ph. Eur. 2.9.3. Residual solvents, where applicable, are controlled under VICH GL18. The terminal finished product is a film-coated or uncoated veterinary tablet administered orally; if film coating is used, a 12–20% w/w aqueous coating dispersion in a side-vented pan at 45–55°C exhaust temperature is typical. Published data for this specific configuration of Cajie Powder is limited; therefore, the above ranges are to be treated as platform-development brackets rather than product specifications.

What changes when Cajie Powder is transferred from dry blending to aseptic aqueous filling?

Injectable dosage forms impose stricter endotoxin, bioburden, and particulate limits on Cajie Powder than oral lines. The active loading is expressed as concentration, mg/mL; the formula for addition is % w/v = (target dose (mg/mL) / 10), so a 50 mg/mL solution corresponds to 5.0% w/v. Solubility determination in water for injection at 20–35°C is the critical first step; if the API is not freely soluble, pH adjustment with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide, or a co-solvent system limited to ≤20% v/v ethanol or propylene glycol, may be required under stability and safety constraints. The solution is prepared in a stainless steel vessel with a bottom magnetic stirrer, filtered through a 0.45 µm prefilter and then a 0.22 µm PVDF or PES membrane, and filled into Type I borosilicate glass vials. On a 12-nozzle filling line, foaming at the fill tip can produce volume variability greater than ±2%; reducing pump stroke speed to below 60% of maximum and using a positive displacement pump with fill volume feedback reduces this effect. Terminal sterilization at 121°C for 15 min is selected only if forced-degradation studies confirm adequate thermal stability; otherwise aseptic filtration and filling are used. Compliance endpoints include USP <85> bacterial endotoxins, USP <788> particulate matter in injections, Ph. Eur. 2.6.14 bacterial endotoxins, and Ph. Eur. 2.9.19 particulate contamination. In-process controls follow 21 CFR 211.110. The terminal finished product is a sterile injectable solution or, if freeze-dried, a lyophilized cake for reconstitution. For lyophilization, the freeze-dryer shelf temperature is ramped from −40°C to 20°C over 18–24 h at chamber pressure 50–100 µbar, and final moisture content should not exceed 1.0% unless otherwise specified in the dossier.

Encapsulation of Cajie Powder on a dosator-type capsule filler is controlled more by the flow function coefficient of the final blend than by API assay alone. The blend is prepared by geometric dilution of Cajie Powder with lactose monohydrate, microcrystalline cellulose, crospovidone, and magnesium stearate; the API addition ratio is determined by capsule size and target dose, % w/w = (target dose (mg) / total fill weight (mg)) × 100. For a size 1 capsule with a fill weight of 300–400 mg, a 100 mg dose corresponds to 25–33% w/w, but published data for this specific configuration of Cajie Powder is limited and the final ratio must be confirmed by filling trials. The powder mixture is sieved through a 0.8 mm mesh, blended in a V-blender at 20–25 rpm for 15–20 min, and filled on a dosator or auger-type encapsulator at 60–80 strokes/min. Weight variation must meet USP <905> or Ph. Eur. 2.9.40; capsule moisture is monitored to prevent brittleness of hard gelatin shells, with equilibrium moisture between 45–55% RH in the filling suite. Process experience indicates that static charge on the API can cause powder carry-over into the sealing ring; grounding the filling station and maintaining ambient RH at 50–60% reduces this failure mode. If the blend flow function coefficient is below 4 by shear cell testing, a glidant such as colloidal silicon dioxide at 0.1–0.5% w/w is introduced. The terminal finished product is a hard gelatin or HPMC veterinary capsule. In-process sampling follows 21 CFR 211.110, and residual solvent control, if organic granulating agents are used prior to encapsulation, remains aligned with VICH GL18.

Medicated Premix Homogeneity and the Geometric Dilution Sequence

Cajie Powder incorporated into a medicated premix must be dispersed across a carrier to achieve blend uniformity before final feed dilution. The formulation addition ratio is expressed as grams of Cajie Powder per kilogram of carrier or final feed. A typical working bracket for a concentrated premix is 10–50 g/kg; the final feed inclusion rate is calculated from the approved veterinary label dose and daily feed intake, mg/kg body weight per day, and not from a fixed percentage. Because total intake varies by species, the formula is final feed inclusion (g/tonne) = (daily dose (mg/kg) × body weight (kg) × 1,000) / daily feed intake (g). If a premix is later diluted to 1:10 or 1:100 in feed, the mixing sequence is a stepwise geometric dilution using a double ribbon mixer with capacity matched to 80% of nominal volume. A 1-tonne ribbon mixer typically requires 20–25 min of total mixing at 20–30 rpm to achieve a coefficient of variation ≤5%; sampling at 10 points with a sampling thief after discharge confirms homogeneity. If segregation occurs during transfer, pneumatic conveying is avoided in favor of gravity feed or low-velocity screw conveying below 1 m/s. Mineral oil at 0.5–1.0% w/w may be sprayed onto the carrier to reduce dust and improve API adhesion. Compliance is anchored to 21 CFR 225 current good manufacturing practice for medicated feed, 21 CFR 558 new animal drugs for use in animal feeds where applicable, and EU 2019/4/EU on medicated feed. The terminal finished product is a medicated feed premix packed in multiwall paper bags with a polyethylene liner, intended for subsequent mixing at the feed mill or on-farm use where permitted.

When a dispersible granule form is required for oral dosing in drinking water

Granulation of Cajie Powder is selected when dust reduction, densification, or reconstitution behavior is required for oral administration via drinking water. The addition ratio in the dry granule is set by the desired sachet dose and the total granule mass; for a 500 mg Cajie Powder sachet filled to 2,000 mg, the ratio is 25% w/w. Fluid-bed top-spray granulation is performed with an aqueous binder solution at 2–5% w/v, spray rate 10–20 g/min, inlet air temperature 55–65°C, product temperature 30–35°C, and outlet relative humidity 20–30%. The endpoint is controlled by loss on drying, typically 2.0–3.0%; overdrying below 1.0% can increase friability, whereas moisture above 3.5% may cause agglomeration in storage. Granule flow is measured by Ph. Eur. 2.9.36, and particle size distribution is maintained with ≥80% of granules between 150 µm and 850 µm. The finished granules are filled into sachets under nitrogen flushing if oxygen-sensitive; a desiccant is not always compatible and should be omitted unless stability data support its use. Content uniformity of the sachets is assessed by Ph. Eur. 2.9.40 or USP <905>. The downstream production process includes sieving, blending, fluid-bed granulation, drying, sieving of dry granules through a 1.0 mm screen, and packing on a vertical form-fill-seal machine with seal temperature 160–180°C for polyethylene terephthalate/aluminum/low-density polyethylene laminates. The terminal finished product is a dispersible granule sachet reconstituted in drinking water; published data for this specific configuration of Cajie Powder is limited, so process validation batches must establish the precise spray-rate and moisture endpoints.

Buffering limits, cosolvent tolerance, and light stability in oral solution compounding

Cajie Powder formulated as an oral solution is dissolved in purified water at 30–40°C under continuous agitation. The addition ratio is expressed as g/L; a 10 g/L solution equals 1.0% w/v. Buffer selection is limited to systems that maintain pH between 4.0 and 6.5 unless forced-degradation data support a wider range; citrate-phosphate or acetate buffers at 10–50 mM are typical. If the API has low aqueous solubility, a cosolvent system of propylene glycol or glycerol at ≤20% v/v is screened, but higher cosolvent content may pose palatability and regulatory constraints. An antioxidant such as sodium metabisulfite at 0.05–0.1% w/w or disodium edetate at 0.01–0.05% w/w may be added only if oxygen-sensitivity data demonstrate a decline of assay beyond specification under accelerated conditions. The solution is filtered through a 5 µm or 10 µm clarification filter and filled into amber polyethylene terephthalate bottles with child-resistant closures. Filling line experience shows that foaming in a rotary piston filler at speeds above 80 bottles/min can lead to underfill; reducing filler speed and using sub-surface nozzles stabilizes delivery. Storage boundaries include protection from light and controlled room temperature 20–25°C; freeze-thaw cycling is not recommended unless specifically validated. Compliance endpoints include USP <1664> assessment of drug product leachables for packaging, 21 CFR 211.166 stability testing, and, where the solution is added to drinking water, 21 CFR 558 or EU 2019/4/EU for medicated water. The terminal finished product is a ready-to-use oral solution or a concentrated solution for dilution before administration.